All GLG News Analyses Filed Under: Cardiology

Zetia Now Off Best Practices List for MI Prevention, But is Niaspan > Diet?

November 15, 2009

Analysis by: GLG Expert Contributor

Analysis of:Another Vytorin Mess For Merck | www.forbes.com

Abbott Laboratories' (ABT.N) Niaspan, though inexpensive and older, lowered HDL and shrunk artery diameter in heart patients more effectively and safely than Merck & Co's (MRK.N) moderately expensive Zetia.Though there is little reason for doctors to prescribe Zetia now, there are real cautions about Niaspan that many people with liver concerns will appreciate.  And so will their physicians.An alternative and winning intervention, essentially unexplored by Pharma, is diet.

Percutaneous valve repair – next battle among cardiovascular device companies?

October 4, 2009

Analysis by: GLG Expert Contributor

Analysis of:Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com

By acquiring promising technology in the percutaneous valve arena, as well as enjoying an already established reputation among interventional cardiologists, Abbott will position itself as a major player in an emerging technology market, and become a comprehensive provider for interventional cardiology solutions.

Will the alternative become a leader?

October 1, 2009

Analysis by: GLG Expert Contributor

Analysis of:EMEA recommends approval of Sanofi-aventis' dronedarone for atrial fibrillation | www.pharmabiz.com

Introducing dronedarone in treatment of atrial fibrillation will provide solution for  many patients with atrial fibrillation who were undertreated due to their contraindications for amiodarone or it's adverse effects.

A new treatment for a major problem.

September 30, 2009

Analysis by: GLG Expert Contributor

Analysis of:ACC: Device May Prevent Stroke in AF Patients | www.medpagetoday.com

Atrial fibrillation is a very common condition that significantly increase the risk of stroke, especially in the older population. Vitamin K antagonists are the only current effective treatment in the higher risk population to reduce stroke. Any new treatment has a huge potential to help reduce risk, and there is nothing else on the horizon to treat this condition.

How much market will MADIT-CRT drive?

September 30, 2009

Analysis by: GLG Expert Contributor

Analysis of:Cardiac-Resynchronization Therapy for the Prevention of Heart Failure Events | content.nejm.org

While this trial had a positive endpoint, it was not a mortality endpoint.   A major defect is a lack of a medical therapy alone arm.  That said, prevention of heart failure episodes is a laudable goal and given the expense to the US system of CHF, this could be a worthwhile treatment, however the number of patients to benefit will be quite small.

Convenient for patients, and maybe for doctors

September 26, 2009

Analysis by: GLG Expert Contributor

Analysis of:Novartis gets FDA approval for combo pill valturna to treat high BP | www.pharmabiz.com

Undoubtedly powerful combination which will help control BP in many patients who have resistant or difficult to control hypertension.

New twist in ABCD algorithm

September 21, 2009

Analysis by: GLG Expert Contributor

Analysis of:Novartis gets FDA approval for combo pill valturna to treat high BP | councils.glgroup.com

The FDA have approved a combination of Aliskiren and Valsartan in a fixed dose preparation for the treatment of hypertension. Although initial safety data show efficacy and tolerability in an 8-week study, outcome data on real-life use and in "non-standard" cases of hypertension or other disorders suggests caution be the watchword. Where the 'R' fits into the 'ABCD' algorithm is unclear, as the B is already on the way out and it also lowers renin.

The Logical Next Step for Abbott

September 15, 2009

Analysis by: GLG Expert Contributor

Analysis of:Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com

With this acquisition Abbott establishes its position as a major player in the field of interventional cardiology and treatment of structural heart disease.The field of structural heart disease therapy is the fastest growing area of interventional cardiology and Abbott is getting in at the ground floor.In addition to Edwards and Medtronic which have aortic valve stents in the pipeline, the Evalve system is the most advanced valve repair system.

Abbot will benefit in long run with acquisition of Evalve.

September 15, 2009

Analysis by: GLG Expert Contributor

Analysis of:Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com

The acquisition will definitely have a significantly beneficial effect on the market standing as well as product portfolio of Abbot. Even though at the present time this technique developed by Evalve Inc. is useful only for a very small subset of patients, eventually Abbott can develop it further to extend it to a bigger group and therefore in the long run it will be able to win a bigger market share.

Good idea in a large company

September 14, 2009

Analysis by: GLG Expert Contributor

Analysis of:Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com

Good ideas and good products are better improved and marketed as a products of a large company, but....

Page : 12345678910Next1 to 10 of 598